NCT02964104View on ClinicalTrials.gov

A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

December 12, 2017

Study Completion Date

December 12, 2017

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

Insulin icodec

Administered once weekly subcutaneously (s.c., under the skin) for 35 days

DRUG

placebo

Administered once daily subcutaneously for 35 days

DRUG

insulin degludec

Administered once daily subcutaneously for 35 days

DRUG

placebo

Administered once weekly subcutaneously for 35 days

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY